Uppsala, Sweden, April 1, 2019. Biovica receives an additional patent on the US market for the company PCR-based product.
Significant events during the third quarter · Abstract was presented at San Antonio Breast Cancer Symposium · New office and staff in USA Significant events after the end of the period · Abstract to be presented at AACR in April · Shares now traded on Nasdaq First North Premier · Lars Holmqvist elected as new Chairman · Two new customers, a pharmaceutical company and a CRO, and sales of SEK 1.5 million.
Uppsala, Sweden, March 20, 2019. Lars Holmqvist was elected Chairman of the Board and a warrant program of 175,000 options to the Board was approved.
Uppsala, the 19th of March 2019. Two new customers have purchased DiviTum®-kits in order to evaluate response to treatment in breast cancer studies. The customers are pharma- and CRO-companies (Contract Research Organization) based in US and Europe.
On March 21, 2018, at 08:00 am CET, Biovica International AB (publ) will publish its interim report for the third quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 09:00 am CET. The event will be hosted by Biovica’s CEO Anders Rylander and CFO Cecilia Driving. The presentation will be held in English.
Uppsala, March 4, 2019. Biotechnology company Biovica announces today that Nasdaq has approved the company’s application to move from Nasdaq First North to be listed on Nasdaq First North Premier. The transition is an important part of the ambition to be listed on the stock exchange’s main list. The trading of Biovica’s share on Nasdaq First North Premier begins on Monday the 4th of March 2019.
DiviTum provides first biomarker evidence for evaluating palbociclib efficacy in new clinical study presented at AACR
New DiviTum results from a clinical study led by Dr Luca Malorni from the Prato Hospital, Italy will be presented at the American Association of Cancer Research annual meeting, 29 March-3 April, in Atlanta. The study results show that DiviTum can evaluate palbociclib treatment responses in women with breast cancer, supporting the potential of the biomarker as a clinically valuable technology for evaluating the effects of a new, targeted breast cancer therapy.
Lars Holmqvist is nominated to be elected as chairman for Biovica at an upcoming extra shareholders meeting on the 20th of March 2019. Lars will replace Göran Brorsson, who wishes to reduce his workload.
Uppsala, Sweden, February 4, 2019. Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, announced today that the company has certified their Quality System according to the ISO13485:2016 standard for the development, manufacturing and sale of DiviTum® at the yearly surveillance audit with Biovica’s notified body.
Biovica carries out a project at Testa Center in order to scale up production to meet expected demand
Uppsala, Sweden, January 31, 2019. The biotech company Biovica, develops and commercializes blood-based biomarker assays that improve the monitoring of modern cancer therapies and better predict patient outcome, takes the next step in their expansion plan. Biovica will scale up production in the newly built facilities at Testa Center in Uppsala to meet the future demand from customers.